Kaan Tugberk Ozdemir

Kaan Tugberk Ozdemir

Auto-generated profile, based on publicly available information

Kaan Tugberk Ozdemir

Department of Neurosurgery Medicana International Izmir Hospital Izmir Türkiye

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Research Square
Verified
Preprint
Open access
PDF file
KOKaan Tugberk Ozdemir
Kaan Tugberk Ozdemir
IBIsmail Bozkurt
Ismail Bozkurt
Background. This report examines the rare phenomenon of spontaneous regression of a lumbar perineural cyst. Lumbar perineural cysts, typically associated with nerve root compression, are generally managed surgically. However, instances of non-surgical resolution have been documented. Case Presentation. A 54-year-old male presented with lower back and left leg pain, with MRI revealing a perineural cyst at the left L4-L5 level. Choosing conservative management, the patient experienced an unexpected and swift regression of the cyst, confirmed by follow-up MRI. Conclusions. This case illustrates the potential for conservative management in lumbar perineural cysts and underscores the importance of individualized patient care. It challenges the traditional surgical preference and advocates for flexible, patient-centered treatment approaches in spinal pathology.

16 July 2026 in Brain and Behavior
Verified
Journal Article
Open access
KÖKaan Tuğberk Özdemir
Kaan Tuğberk Özdemir
ESEmre Söylemez
Emre Söylemez
Background: Evidence suggests that neck pain and cervical pathologies may contribute to auditory disorders; however, auditory functions in individuals with forward head posture (FHP) have been insufficiently studied. This study aimed to explore hearing thresholds, self‐reported auditory difficulties, central auditory processing measures, and the presence of tinnitus and hyperacusis in individuals with FHP with and without chronic neck pain compared with controls. Methods: Fifty individuals with FHP were included and classified into two groups according to the presence of nonspecific chronic neck pain: FHP with neck pain and FHP‐only. Fifty individuals without FHP or neck pain constituted the control group. Tinnitus presence was recorded in all participants. Hearing levels were assessed using pure‐tone audiometry, and subjective hearing difficulties were evaluated with the Turkish version of the Amsterdam Inventory for Auditory Disability and Handicap (T‐AIADH). Central auditory processing was examined using the Modulation Detection Test (MDT) and the Temporal Fine Structure–Adaptive Frequency (TFS–AF) test. Sound tolerance was assessed using the Khalfa Hyperacusis Questionnaire. Results: No significant differences were observed among the groups in pure‐tone hearing thresholds, MDT, TFS–AF, or hyperacusis scores ( p > 0.05). However, T‐AIADH scores were significantly higher in the FHP with neck pain group than in the other groups (raw p = 0.022; Holm‐adjusted p = 0.044). Tinnitus prevalence was also significantly higher in this group ( p = 0.003). Conclusion: This study did not detect significant differences in objective auditory measures among individuals with FHP‐only and controls. However, individuals with FHP and neck pain reported greater subjective hearing difficulties and a higher prevalence of tinnitus, highlighting the importance of considering neck pain in FHP evaluation.

26 August 2024 in Clinical Neuropharmacology
Verified
Journal Article
Closed access
ŞBŞU** B*****
ŞU** B*****
KOKaan Tugberk Ozdemir
Kaan Tugberk Ozdemir
EYEmiş Cansu Yaka
Emiş Cansu Yaka
ÖDÖmer Demir
Ömer Demir
HAHuriye Aydın
Huriye Aydın
UŞUfuk Şener
Ufuk Şener
Objectives: The aim of the study is to assess the prevalence and clinical features of headache in patients treated with botulinum toxin for blepharospasm and hemifacial spasm. In addition, our secondary aim was to identify potential factors influencing the development of these headaches Methods: A total of 70 patients who were treated with on a botulinum toxin A for dystonia treatment in our clinic between January 2023 and March 2023 were retrospectively screened, and the clinical and demographic characteristics of the patients who reported headache complaints after the last botulinum toxin treatment were examined. Results: Headache was reported in 8 (%11.4) of the 70 patients included in the study. Of the 8 patients who reported headaches, 6 (%75) had the onset of the complaint within the first 24 hours. There was no significant correlation between headache occurrence and factors like age, gender, diagnosis, botulinum toxin dosage, application site, comorbid diseases, or hypertension. However, a statistically significant link was observed between the intensity of pain experienced during treatment and the frequency of headaches after the treatment Conclusions: Botulinum toxin treatment can lead to short-term headaches in some patients, starting early after the procedure. The significant link between the frequency of these headaches and the pain experienced during injection highlights the need to examine factors like the volume and dilution rate of the toxin, the solvent used, treatment area, treatment purpose, patient characteristics, and the physician's technique. It is important to study these aspects by comparing them across a large patient group and control subjects.


17 October 2023
Verified
Preprint
Open access
PDF file
KOKaan Ozdemir
Kaan Ozdemir
Background: Parkinson’s disease (PD) is a pervasive neurodegenerative disorder that significantly impacts the quality of life of affected individuals. Current treatment options such as pharmacological interventions and deep brain stimulation have notable limitations in their efficacy and are linked with various side effects. This review aims to examine the potential of innovative cranial nerve stimulation and neuromodulation techniques for treating PD. Methods: A comprehensive literature search was conducted using relevant keywords across major databases to identify recent advancements in cranial nerve stimulation devices, stimulation protocols, and their clinical applications for PD. The process aimed to collate information on emerging technologies, including non-invasive and minimally invasive devices, offering more targeted and personalized treatment approaches. Results: The review highlights innovative devices and stimulation protocols showing potential in PD treatment. The safety and efficacy of these techniques were compared with conventional treatments based on results from clinical trials. We analyzed the advantages and limitations of these next-generation cranial nerve stimulation and neuromodulation techniques, with a special focus on their potential to improve patient outcomes and enhance quality of life. Conclusion: Next-generation cranial nerve stimulation and neuromodulation techniques hold substantial promise for more effective and better-tolerated PD treatments. These innovative strategies potentially pave the way for novel clinical applications and improved patient care. The review also discusses translational challenges and suggests future research directions to maximize the therapeutic potential of these promising techniques in PD treatment.